Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Clin Cancer Res. 2018 Mar 14;24(11):2642–2652. doi: 10.1158/1078-0432.CCR-17-2778

Figure 1.

Figure 1

(A) Antibody panel raised following vaccination of mice with survivin peptide (SVN53-67/M57) present in SurVaxM. Relative binding of different hybridoma clones to immobilized survivin peptide (ELISA) is displayed with indicated amount of supernatant volume (MFI = mean fluorescence index). (B) Western blot of whole cell lysates from human embryonic kidney 293T cells with indicated antibodies demonstrating the dominant 16.5 kD survivin species. (C) Western blot of purified recombinant GST or GST-survivin proteins detected by the indicated antibodies (GST, glutathione-S-transferase). (D) Slot blots detecting filter-immobilized KLH carrier protein and scrambled, mutant and wild type survivin peptides with indicated survivin antibodies. (E) Competition blocking of monoclonal antibodies pre-incubated with peptides (left) and then used to detect filter-immobilized, wild type SVN53-67 peptide. (F) AlphaLISA assay performed to determine relative affinity of purified 2C2 and 30H3 antibodies forSVN53-67 peptide.